$VNDA
Vanda Pharmaceuticals Inc.

2021 Q1 Form 10-Q Financial Statement

#000134717821000015 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $62.67M $58.00M
YoY Change 8.05% 21.56%
Cost Of Revenue $6.030M $5.210M
YoY Change 15.74% 1.9%
Gross Profit $56.64M $52.42M
YoY Change 8.04% 24.17%
Gross Profit Margin 90.38% 90.38%
Selling, General & Admin $29.80M $37.02M
YoY Change -19.51% 19.31%
% of Gross Profit 52.61% 70.62%
Research & Development $16.13M $15.53M
YoY Change 3.89% 16.94%
% of Gross Profit 28.48% 29.62%
Depreciation & Amortization $345.0K $351.0K
YoY Change -1.71% 5.72%
% of Gross Profit 0.61% 0.67%
Operating Expenses $45.93M $52.55M
YoY Change -12.6% 18.6%
Operating Profit $10.34M -$125.0K
YoY Change -8372.8% -94.01%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $90.00K $1.370M
YoY Change -93.43% -8.05%
Pretax Income $10.43M $1.241M
YoY Change 740.29% -306.15%
Income Tax $1.800M $800.0K
% Of Pretax Income 17.26% 64.46%
Net Earnings $8.650M $486.0K
YoY Change 1679.84% -179.41%
Net Earnings / Revenue 13.8% 0.84%
Basic Earnings Per Share $0.16 $0.01
Diluted Earnings Per Share $0.15 $0.01
COMMON SHARES
Basic Shares Outstanding 55.15M shares 53.81M shares
Diluted Shares Outstanding 56.51M shares 54.87M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $378.2M $312.3M
YoY Change 21.08% 16.61%
Cash & Equivalents $72.13M $64.95M
Short-Term Investments $306.0M $247.4M
Other Short-Term Assets $10.30M $17.80M
YoY Change -42.13% 58.93%
Inventory $1.361M $1.320M
Prepaid Expenses
Receivables $31.47M $29.27M
Other Receivables $0.00 $0.00
Total Short-Term Assets $421.2M $360.7M
YoY Change 16.76% 17.7%
LONG-TERM ASSETS
Property, Plant & Equipment $3.840M $3.877M
YoY Change -0.95% -9.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $86.70M $90.40M
YoY Change -4.09% 2052.38%
Total Long-Term Assets $122.0M $127.8M
YoY Change -4.55% 186.06%
TOTAL ASSETS
Total Short-Term Assets $421.2M $360.7M
Total Long-Term Assets $122.0M $127.8M
Total Assets $543.2M $488.5M
YoY Change 11.19% 39.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.300M $4.900M
YoY Change 8.16% 6.52%
Accrued Expenses $56.10M $21.10M
YoY Change 165.88% -61.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.78M $59.22M
YoY Change 4.33% -0.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.655M $778.0K
YoY Change 241.26% 380.25%
Total Long-Term Liabilities $2.655M $778.0K
YoY Change 241.26% 380.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.78M $59.22M
Total Long-Term Liabilities $2.655M $778.0K
Total Liabilities $75.56M $72.14M
YoY Change 4.75% -0.85%
SHAREHOLDERS EQUITY
Retained Earnings -$188.7M -$220.2M
YoY Change -14.31% -34.63%
Common Stock $656.1M $635.8M
YoY Change 3.2% 3.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $467.6M $416.4M
YoY Change
Total Liabilities & Shareholders Equity $543.2M $488.5M
YoY Change 11.19% 39.12%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $8.650M $486.0K
YoY Change 1679.84% -179.41%
Depreciation, Depletion And Amortization $345.0K $351.0K
YoY Change -1.71% 5.72%
Cash From Operating Activities $9.193M -$907.0K
YoY Change -1113.56% -109.41%
INVESTING ACTIVITIES
Capital Expenditures $130.0K $373.0K
YoY Change -65.15% -5.09%
Acquisitions
YoY Change
Other Investing Activities $200.0K $20.70M
YoY Change -99.03% -157.34%
Cash From Investing Activities $71.00K $20.30M
YoY Change -99.65% -155.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.849M $479.0K
YoY Change 286.01% 167.6%
NET CHANGE
Cash From Operating Activities $9.193M -$907.0K
Cash From Investing Activities $71.00K $20.30M
Cash From Financing Activities $1.849M $479.0K
Net Change In Cash $11.10M $19.88M
YoY Change -44.17% -174.65%
FREE CASH FLOW
Cash From Operating Activities $9.193M -$907.0K
Capital Expenditures $130.0K $373.0K
Free Cash Flow $9.063M -$1.280M
YoY Change -808.05% -113.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001347178
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Pennsylvania Avenue NW
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0491827
CY2021Q1 dei Entity File Number
EntityFileNumber
001-34186
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
VANDA PHARMACEUTICALS INC.
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300 E
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20037
CY2021Q1 dei City Area Code
CityAreaCode
202
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
734-3400
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
VNDA
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72132000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61031000 USD
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55564214 shares
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
306030000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
306709000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31474000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30036000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
1361000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10227000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10089000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
421224000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
409145000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3840000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4136000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10194000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10459000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21189000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21559000 USD
CY2021Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
80355000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81516000 USD
CY2021Q1 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
6389000 USD
CY2020Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
6641000 USD
CY2021Q1 us-gaap Assets
Assets
543191000 USD
CY2020Q4 us-gaap Assets
Assets
533456000 USD
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
26105000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
CY2021Q1 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
35679000 USD
CY2020Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
34427000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
61784000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65936000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11125000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11497000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2655000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2757000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
75564000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
80190000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55560214 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55560214 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54865092 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54865092 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
656057000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
650300000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
192000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
467627000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188678000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197328000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
543191000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
533456000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62669000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
58000000 USD
CY2021Q1 us-gaap Revenues
Revenues
62669000 USD
CY2020Q1 us-gaap Revenues
Revenues
58000000 USD
CY2021Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6030000 USD
CY2020Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
5207000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16131000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15527000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29797000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37021000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
52328000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
58125000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
10341000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-125000 USD
CY2021Q1 us-gaap Other Income
OtherIncome
87000 USD
CY2020Q1 us-gaap Other Income
OtherIncome
1366000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
10428000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1241000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1778000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
755000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55145789 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53806317 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56505087 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54870146 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-47000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-13000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
1000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
705000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
160000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
532000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8603000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1018000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1849000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3909000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
467627000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
479000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3944000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
532000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
416386000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
345000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
351000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3909000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3944000 USD
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-490000 USD
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
287000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
12000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000 USD
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1160000 USD
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
879000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-295000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-314000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1483000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2905000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-50000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3524000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-42000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-76000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5272000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1795000 USD
CY2021Q1 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
649000 USD
CY2020Q1 vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
1184000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9193000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-907000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
130000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
373000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93060000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
41400000 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
93261000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
62073000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
71000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20300000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1849000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
479000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1849000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
479000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-15000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11098000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19877000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61613000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72711000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65527000 USD
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72132000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64950000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72711000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65527000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62669000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
58000000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
305824000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
213000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306030000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
306504000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
216000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306709000 USD
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
306030000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
306709000 USD
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
207000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
66000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1154000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1214000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
1361000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q1 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
742000 USD
CY2020Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
744000 USD
CY2021Q1 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
3905000 USD
CY2020Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
4045000 USD
CY2021Q1 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
303000 USD
CY2020Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
302000 USD
CY2021Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
4950000 USD
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5091000 USD
CY2021Q1 vnda Inventory
Inventory
6311000 USD
CY2020Q4 vnda Inventory
Inventory
6371000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
CY2021Q1 vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P90D
CY2021Q1 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
7231000 USD
CY2020Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
6173000 USD
CY2021Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5318000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5817000 USD
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5164000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5052000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4113000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10951000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2126000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2117000 USD
CY2021Q1 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
350000 USD
CY2020Q4 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
350000 USD
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1803000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1049000 USD
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
26105000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
34000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
81000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
158000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
158000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
192000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
CY2021Q1 vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
CY2021Q1 vnda Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors
ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
P4Y
CY2021Q1 vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
CY2021Q1 vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
CY2021Q1 vnda Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments
SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
36 installment
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.95
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.73
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1800000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
500000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3909000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3944000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.46
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.52
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M2D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0073
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0137
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1800000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000 USD
CY2021Q1 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-300000 USD
CY2020Q1 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
400000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55145789 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53806317 shares
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1359298 shares
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1063829 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56505087 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54870146 shares
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2137110 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3095224 shares

Files In Submission

Name View Source Status
0001347178-21-000015-index-headers.html Edgar Link pending
0001347178-21-000015-index.html Edgar Link pending
0001347178-21-000015.txt Edgar Link pending
0001347178-21-000015-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20210331.htm Edgar Link pending
vnda-20210331.xsd Edgar Link pending
vnda-20210331_cal.xml Edgar Link unprocessable
vnda-20210331_def.xml Edgar Link unprocessable
vnda-20210331_htm.xml Edgar Link completed
vnda-20210331_lab.xml Edgar Link unprocessable
vnda-20210331_pre.xml Edgar Link unprocessable
vndaex311331202110q.htm Edgar Link pending
vndaex312331202110q.htm Edgar Link pending
vndaex321331202110q.htm Edgar Link pending